SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses

Mostrar otras versiones (1)

BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Suhandynata, Raymond T, Bevins, Nicholas J, Tran, Jenny T, Huang, Deli, Hoffman, Melissa A, Lund, Kyle, Kelner, Michael J, McLawhon, Ronald W, Gonias, Steven L, Nemazee, David, Fitzgerald, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409063/
https://www.ncbi.nlm.nih.gov/pubmed/34170314
http://dx.doi.org/10.1093/jalm/jfab080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409063/
https://www.ncbi.nlm.nih.gov/pubmed/34170314
http://dx.doi.org/10.1093/jalm/jfab080

Ejemplares similares